Ensign Peak Advisors’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Ensign Peak Advisors’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-3,681	Closed	-$419K	–	1807
2022 Q4	$419K	Sell	3,681 -103,758	-97%	-$8.62M	﹤0.01%	1656
2022 Q3	$6.65M	Sell	107,439 -25,563	-19%	-$1.79M	0.02%	462
2022 Q2	$10.6M	Buy	133,002 +45,038	+51%	+$4.27M	0.03%	375
2022 Q1	$9.26M	Sell	87,964 -18,649	-17%	-$1.82M	0.02%	437
2021 Q4	$11.5M	Buy	106,613 +74,407	+231%	+$8.12M	0.02%	433
2021 Q3	$3.53M	Buy	32,206 +24,997	+347%	+$2.6M	0.01%	803
2021 Q2	$675K	Hold	7,209	–	–	﹤0.01%	1541
2021 Q1	$664K	Sell	7,209 -120,358	-94%	-$10.2M	﹤0.01%	1544
2020 Q4	$9.33M	Sell	127,567 -7,359	-5%	-$547K	0.02%	431
2020 Q3	$10.5M	Sell	134,926 -10,558	-7%	-$726K	0.03%	437
2020 Q2	$8.09M	Sell	145,484 -29,140	-17%	-$1.25M	0.02%	474
2020 Q1	$5.17M	Buy	174,624 +60,264	+53%	+$2.04M	0.02%	503
2019 Q4	$4.14M	Buy	+114,360	New	+$3.51M	0.01%	704

Other funds holding HZNP

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

DKCM

Davidson Kempner Capital Management New York $7.33B AUM 56.47% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Ensign Peak Advisors's HZNP Position: Q1 2023 in Review

Ensign Peak Advisors sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q1 2023, closing a stake of 3,681 shares — an estimated $419K sold.

Ensign Peak Advisors first reported a position in HZNP in Q4 2019 and held it in 13 quarters. The position peaked at $11.5M in Q4 2021. 553 funds tracked by Wall St. Rank hold HZNP as of Q1 2023.

Ensign Peak Advisors reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q1 2023 after selling out during the quarter.
Ensign Peak Advisors sold 3,681 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q1 2023, an estimated $419K.
Ensign Peak Advisors first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q4 2019 and held it in 13 quarters.
Ensign Peak Advisors's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $11.5M in Q4 2021.
553 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q1 2023.

Based on Ensign Peak Advisors's 13F filing for Q1 2023, filed 15 May 2023.